Crescent Biopharma, Inc
Price
FilingsNewest: 424B3, ProspectusJul 30 →Insiders4 insiders bought $18.2M in 1 open-market buy. 7 insiders sold $1.2M, all 7 sales on a 10b5-1 plan.→Financing →PeersClosest companies: APGE, VRDN, CGEM→
From the filings
Figures
- Revenue
- $11.9Mlast 12 months
- Net income
- −$96.0Mlast 12 months
- Operating cash flow
- −$69.6Mlast 12 months
- Cash and equivalents
- $171.6Mat the last balance sheet
- Shares outstanding
- 27.8M shareson issue